IP Library Granted Patent US 11,827,928
Granted Patent B2
US 11,827,928 · App. 17/396,171 · Granted Nov 28, 2023

Methods for high level multiplexed polymerase chain reactions and homogeneous mass extension reactions

Inventors: Martin Beaulieu (San Diego, CA); Dirk Johannes Van den Boom (Encinitas, CA)
Assignee: AGENA BIOSCIENCE, INC.
C12Q1/6858C12Q1/6844C12Q1/6872C12Q1/6874C12Q1/6886C12Q1/686C12Q2600/156C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,827,928
App. No.
17/396,171
Granted
Nov 28, 2023
Kind
B2
Abstract

Provided herein are optimized methods for performing multiplexed detection of a plurality of sequence variations. Also provided are methods for performing multiplexed amplification of target nucleic acid.

Claims (22)

1. A multiplex method of genotyping a plurality of polymorphic loci, comprising:

(a) simultaneously amplifying a plurality of nucleic acid-target regions with amplification primer pairs under amplification reaction conditions whereby at least 60% of 7 or more nucleic acid target regions attempted are amplified by 7 or more amplification primer pairs to produce an amplified mixture of nucleic acid-target regions containing polymorphic loci; (b) after (a), contacting the amplified mixture of nucleic acid-target regions with genotyping primers in the presence of at least one chain terminating reagent under primer mass extension reaction conditions whereby the primers are extended up to, or through, the respective polymorphic loci, wherein there is one genotyping primer for each polymorphic locus within a nucleic acid-target region; (c) determining the masses of the extended genotyping primers by mass spectrometry; and (d) based on the masses of the extended genotyping primers determined in (c), determining at least 60% of the genotypes for said 7 or more nucleic acid target regions attempted, thereby genotyping a plurality of polymorphic loci.

2. The method of claim 1 , wherein the mass spectrometry is selected from among Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight (MALDI-TOF), Electrospray Ionization (ESI), Ultraviolet-Matrix-Assisted Laser Desorption/Ionization (UV-MALDI), Infrared-Matrix-Assisted Laser Desorption/Ionization (IR-MALDI), Orthogonal-Time-of-Flight (0-TOF), Axial-Time-of-Flight (A-TOF), Ion Cyclotron Resonance (ICR), Fourier Transform Linear/Reflectron (RETOF), Quadrupole mass spectrometry, Quadrupole ion trap mass spectrometry, and combinations thereof.

3. The method of claim 2 , wherein the mass spectrometry is Matrix Assisted Laser Desorption/Ionization-Time-of-Flight (MALDI-TOF) mass spectrometry.

4. The method of claim 1 , wherein the amplification reaction conditions comprise water, genomic DNA, a buffer, dNTPs, the primer pairs, MgCl 2 , and a polymerase.

5. The method of claim 4 , wherein the concentration of each dNTP is between about 400 μM to about 700 μM.

6. The method of claim 4 , wherein the concentration of each dNTP is about 200 μM.

7. The method of claim 4 , wherein the amplification reaction conditions comprise a free Mg 2+ concentration of between 1.0 mM to 2.0 mM, wherein the free Mg 2+ concentration is equal to the total MgCl 2 concentration less the total combined concentration of the dNTPs.

8. The method of claim 7 , wherein the free Mg 2+ concentration is between 1.1-1.9 mM, between 1.2-1.8 mM, between 1.3-1.7 mM, or between 1.4-1.6 mM.

9. The method of claim 7 , wherein the free Mg 2+ concentration is about 1.5 mM.

10. The method of claim 4 , wherein the ratio of the concentration of MgCl 2 to the concentration of each of the dNTPs is ≤10:1, ≤9:1, ≤8:1, ≤7:1, ≤6:1 or ≤5:1.

11. The method of claim 10 , wherein the ratio of the concentration of MgCl 2 to the concentration of each of the dNTPs is ≤7:1.

12. The method of claim 1 , wherein the amplification reaction conditions comprise about 100 nM primer pairs, and between about 2.6 mM up to about 4.8 mM MgCl 2 .

13. The method of claim 12 , wherein the amplification reaction conditions comprise about 500 μM of each dNTP and about 3.5 mM MgCl 2 .

14. The method of claim 1 , wherein only a single primer pair is utilized to amplify each nucleic acid-target region.

15. The method of claim 1 , wherein between 7 nucleic acid target regions to about 50 or more nucleic acid target regions are attempted to be amplified.

16. The method of claim 1 , wherein the extension reaction conditions comprise at least 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 or more thermocycles.

17. The method of claim 1 wherein, in (d), at least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, up to 100% of the attempted genotypes are determined.

18. The method of claim 1 , wherein the masses of the extended genotyping primers are distinct in an allele-specific manner.

19. The method of claim 1 , wherein the separation between the masses of each of the extended genotyping primers is at least 20 Daltons.

20. The method of claim 1 , wherein the chain terminating reagent comprises a dideoxynucleotide.

21. The method of claim 1 , wherein more than 7 nucleic acid target regions are attempted to be amplified.

Assignments (5)
SECURITY INTEREST Recorded Oct 5, 2023
From: MESA LABORATORIES, INC.; AGENA BIOSCIENCE, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065135/0174 →
CORRECT AN ERROR IN THE COVER SHEET PREVIOUSLY RECORDED ON OCTOBER 27, 2021 WITH REEL 057935 FRAME 0311 TO CORRECT THE NATURE OF CONVEYANCE FROM "CHANGE OF NAME" TO "ASSIGNMENT". Recorded Oct 2, 2023
From: SEQUENOM, INC.
To: BIOSCIENCES ACQUISITION COMPANY
Reel/Frame 065152/0818 →
CHANGE OF NAME Recorded Oct 27, 2021
From: SEQUENOM, INC.
To: BIOSCIENCES ACQUISITION COMPANY
Reel/Frame 057935/0311 →
CHANGE OF NAME Recorded Oct 26, 2021
From: BIOSCIENCES ACQUISITION COMPANY
To: AGENA BIOSCIENCE, INC.
Reel/Frame 057922/0938 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2021
From: VAN DEN BOOM, DIRK; BEAULIEU, MARTIN
To: SEQUENOM, INC.
Reel/Frame 057903/0991 →
Continuity (7)
Continuation 15863644 · Jan 5, 2018
Continuation 14720179 · May 22, 2015
Continuation 13718758 · Dec 18, 2012
Continuation 13193390 · Jul 28, 2011
Continuation 10903268 · Jul 30, 2004
Provisional Application 60492102 · Jul 31, 2003
Related Publication 20220106637A1 · Apr 7, 2022